Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Phase 1
Recruiting
- Conditions
- CNS LymphomaPrimary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 35
- Registration Number
- NCT05351593
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Phase 1
Recruiting
- Conditions
- Primary CNS Lymphoma
- Interventions
- Procedure: Magnetic resonance imaging (MRI)
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 25
- Registration Number
- NCT04656431
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Phase 1
Completed
- Conditions
- Recurrent/Refractory CNSIntraocular Lymphoma
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 14
- Registration Number
- NCT01542918
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath